← DISPATCHES
[WORLD]

Briefing: STAT+: As controversial decisions mount, FDA shuns public advisory meetings

Strategic angle: The FDA is cutting back on public advisory committee meetings, even as the public and other stakeholders seek more transparency.

Editorial Staff · 2026-03-09 · 1 MIN READ

Summary

  • Summary pending editorial review.

Key Facts

  • Key facts pending editorial review.

Sources